论文部分内容阅读
目的:通过临床实验对哌拉西林/他唑巴坦治疗老年呼吸道感染的有效性和安全性进行分析。方法:选取2010年11月至2011年12月我院接收的96例呼老年吸道感染患者,将其分为观察组和对照组,对照组患者采用哌拉西林/舒巴坦进行治疗,观察组采用哌拉西林/他唑巴坦进行治疗,比较两组患者的临床治疗效果。结果:分析比较可得,观察组治疗的总有效率约为85.43%,对照组治疗的总有效率约为66.66%,两组比较,P<0.05,具有统计学意义。两组患者均未出现严重不良反应,药物治疗的安全性较高。结论:哌拉西林/他唑巴坦治疗老年呼吸道感染疗效显著,并能减少不良反应的发生,具有重要临床意义,值得推广应用。
OBJECTIVE: To evaluate the efficacy and safety of piperacillin / tazobactam in the treatment of elderly respiratory infections through clinical trials. Methods: Ninety-six elderly patients with respiratory tract infections were selected from November 2010 to December 2011 in our hospital. The patients were divided into observation group and control group. The control group was treated with piperacillin / sulbactam and observed Group treated with piperacillin / tazobactam, the clinical efficacy of the two groups were compared. Results: Compared with the control group, the total effective rate of the observation group was 85.43%, while the total effective rate of the control group was 66.66%. There was significant difference between the two groups (P <0.05). No serious adverse reactions occurred in both groups, and the safety of drug treatment was high. CONCLUSION: Piperacillin / tazobactam is effective in treating elderly respiratory infections and can reduce the incidence of adverse reactions. It is of great clinical significance and is worth popularizing and applying.